The U.S. FDA announced plans to convene an advisory panel in September to review Grail Inc.'s multi-cancer early detection test. This regulatory step is crucial for the potential market approval of the innovative diagnostic tool.
FDA Schedules Advisory Meeting to Review Grail's Multi-Cancer Test
FDAbiotechcancer testmedical device regulation
